Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Intuniv is a prescription extended-release form of guanfacine. It is a central alpha-2A adrenergic receptor agonist indicated for attention deficit hyperactivity disorder as monotherapy or with stimulant medicines. Current tablets contain 1 mg, 2 mg, 3 mg, or 4 mg.
read more about intuniv ...Guanfacine stimulates central alpha-2A adrenergic receptors. The mechanism responsible for its therapeutic action in attention deficit hyperactivity disorder is not fully established. Its sympatholytic activity can reduce heart rate and blood pressure.
Intuniv has been studied for attention deficit hyperactivity disorder in children and adolescents age 6 through 17. It is used alone or with stimulant medicines. Dose selection is based on body weight, clinical response, and tolerability.
Treatment starts at 1 mg once daily in the morning or evening. The dose can increase by no more than 1 mg per week. The recommended target range is 0.05 to 0.12 mg per kg daily, with total daily doses from 1 mg to 7 mg under current labeling. Tablets are swallowed whole and are not taken with a high-fat meal.
Intuniv can cause low blood pressure, slow heart rate, fainting, sedation, somnolence, and cardiac conduction abnormalities. Abrupt discontinuation can cause clinically significant rebound hypertension and has been associated with hypertensive encephalopathy. The dose is tapered by no more than 1 mg every three to seven days when treatment ends.
Intuniv treats attention deficit hyperactivity disorder as monotherapy or with stimulant medicines.
The starting dose is 1 mg once daily.
Yes. Sedation and somnolence are recognized adverse reactions.
Gradual dose reduction lowers the risk of rebound hypertension after discontinuation.
Effects of Guanfacine Extended Release on Oppositional Symptoms in Children Aged 6?12 Years With Attention-Deficit Hyperactivity Disorder and Oppositional Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/20806988/. Date Accessed October 5, 2026.
Extended-Release Guanfacine Hydrochloride in 6?17-Year-Olds With ADHD: A Randomised-Withdrawal Maintenance of Efficacy Study. https://pubmed.ncbi.nlm.nih.gov/26871297/. Date Accessed October 5, 2026.
Guanfacine: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a601059.html. Date Accessed October 5, 2026.
Guanfacine Extended-Release Tablets Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07a701e2-39b7-4bb1-a7c7-d9baed4ab18a. Date Accessed October 5, 2026.
New Pediatric Labeling Information Database - Intuniv. https://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?id=14F7A847BCED0979E053564DA8C00FF5&rownum=305&sd=labelingdatabase. Date Accessed October 5, 2026.